Avicenna Journal of Phytomedicine

Avicenna Journal of Phytomedicine

Evaluation of anti-giardial and immunomodulatory activities of chloroform extract of Astragalus baba-alliar in experimental Giardia lamblia infection

Document Type : Original Research Article

Authors
1 Department of Pharmacognosy, Lorestan University of Medical Sciences, Khorramabad, Iran
2 Department of Medical Laboratory Techniques, Nasiriyah Technical Institute, Southern Technical University, Nasiriyah 64001, Iraq
3 Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
4 Lorestan University of Medical Sciences, Khorramabad, Iran
Abstract
Objective: This study evaluated the in vitro and in vivo anti-giardial effects of a chloroform extract of the aerial parts of Astragalus baba-alliar (ABCE) against Giardia lamblia.
Materials and methods: Anti-giardial activity of ABCE (100–400 µg/mL) was assessed against cysts and trophozoites. Cytotoxicity was determined in normal intestinal cells (NCM460) and SW480 cell line using MTT assay. In vivo efficacy was evaluated in infected mice compared with metronidazole. Intestinal expression of TNF-α, NF-κB, and IL-1β was analyzed by real-time PCR.
Results: ABCE exhibited dose-dependent in vitro activity, with the highest concentration inducing 100% eosin-positive cysts within 120 min and complete loss of trophozoite viability within 60 min (p < 0.001). Cytotoxicity analysis revealed selective safety, as NCM460 cells were less affected than cancerous SW480 cells. In vivo, ABCE markedly reduced cyst burden in a dose-dependent manner, with 40 mg/kg showing the most pronounced effect (p<0.001). Concomitantly, intestinal inflammatory markers decreased progressively with higher doses of ABCE, from modest reductions at 10 mg/kg to near-baseline levels at 40 mg/kg (TNF-α 1.17, NF-κB 1.08, and IL-1β 0.94-fold change), indicating effective modulation of the host inflammatory response.
Conclusion: ABCE demonstrated potent anti-giardial and anti-inflammatory activity with minimal toxicity to normal cells, supporting its potential as a therapeutic candidate against giardiasis. Further mechanistic and pharmacokinetic studies are warranted to confirm efficacy and safety.
Keywords
Subjects


Articles in Press, Accepted Manuscript
Available Online from 03 August 2026